The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.
Abstract
EST 5275 is a phase II and III study of fluorouracil plus streptozocin (5-FU plus STZ) or doxorubicin in patients with measurable progressive carcinoid tumor. Among one hundred seventy-two cases with no prior chemotherapy and no heart disease, the response rate was 22% for 5-FU plus STZ and 21% for doxorubicin, while the median response duration and median survival were 31 weeks and 64 weeks for the combination and 26 weeks and 48 weeks for doxorubicin. Thirty-three patients who failed 5-FU plus STZ crossed over to doxorubicin and achieved an 18% response. Of the thirty-five patients who failed on doxorubicin, 29% responded to 5-FU plus STZ. Hematologic toxicity was similar for both treatments; however, the 5-FU plus STZ patients experienced more vomiting but acceptable renal toxicity. Both chemotherapy regimens have antitumor activity in carcinoid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Carcinoids: The association of histologic growth pattern and survival
Johnson, L. A., Lavin, P. T., Moertel, C. G., Weiland, L. H., Dayal, Y., Doos, W. G., Geller, S. A., Cooper, H. S., Nime, F. A., Massé, S., et al. (1983) · Cancer · doi:10.1002/1097-0142(19830301)51:5<882::aid-cncr2820510522>3.0.co;2-8 · Cited by 117
Self-citation
Cited by
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Current Status of Gastrointestinal Carcinoids
Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N., & Shapiro, M. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.038 · Cited by 848
Kulke, M. H., & Mayer, R. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401107 · Cited by 741
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Kulke, M. H., Stuart, K., Enzinger, P. C., Ryan, D. P., Clark, J. W., Muzikansky, A., Vincitore, M., Michelini, A., & Fuchs, C. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6046 · Cited by 513
Metadata
- Authors
- Engstrom, P. F., Lavin, P. T., Moertel, C. G., Folsch, E., & Douglass, H. O.
- Venue
- Journal of Clinical Oncology
- Published
- 1984-11
- Volume
- 2
- Issue
- 11
- Pages
- 1255-1259
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1771569409
- Cited by
- 270
- References
- 4
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. https://app.cochat.ai/papers/10.1200/jco.1984.2.11.1255
- The paper
- Engstrom, P. F., Lavin, P. T., Moertel, C. G., Folsch, E., & Douglass, H. O. (1984). Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1984.2.11.1255
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.